Abwiz Bio's COO and CSO, Toshi Maruyama, has nearly 20 years of experience in antibody development, having held senior scientist and management roles at Calmune, Nitto Denko Technical, and Alexion Antibody Technologies. He obtained his MD and PhD degree from Tokyo Medical and Dental University, studying molecular biology and immunology. Maruyama's expertise lies in phage display and recombinant antibody technologies, which Abwiz Bio utilizes to develop research tools, diagnostics, and therapeutics. The company's unique cloning method, WizAmp™, and rabbit monoclonal antibodies from RabWiz™ technology provide highly-specific and high-affinity antibodies that have a more diverse recognition of epitopes on antigens than competitors. This facilitates reliable detection of targets that might have been missed by hybridoma technology or other phage display methods.